MBB Public Markets I LLC Purchases New Position in Zimmer Biomet Holdings, Inc. $ZBH

MBB Public Markets I LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,838 shares of the medical equipment provider’s stock, valued at approximately $321,000.

Several other large investors have also added to or reduced their stakes in ZBH. United Services Automobile Association purchased a new stake in Zimmer Biomet in the 1st quarter valued at about $525,000. Ashton Thomas Private Wealth LLC increased its stake in Zimmer Biomet by 13.4% in the 1st quarter. Ashton Thomas Private Wealth LLC now owns 10,280 shares of the medical equipment provider’s stock valued at $1,166,000 after buying an additional 1,218 shares during the last quarter. USS Investment Management Ltd increased its stake in Zimmer Biomet by 7.8% in the 1st quarter. USS Investment Management Ltd now owns 50,466 shares of the medical equipment provider’s stock valued at $5,713,000 after buying an additional 3,642 shares during the last quarter. UniSuper Management Pty Ltd increased its stake in Zimmer Biomet by 1.0% in the 1st quarter. UniSuper Management Pty Ltd now owns 24,025 shares of the medical equipment provider’s stock valued at $2,719,000 after buying an additional 242 shares during the last quarter. Finally, Sandler Capital Management purchased a new stake in Zimmer Biomet in the 1st quarter valued at about $4,731,000. Institutional investors own 88.89% of the company’s stock.

Insiders Place Their Bets

In related news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the transaction, the insider directly owned 20,424 shares in the company, valued at approximately $1,940,280. The trade was a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ZBH shares. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. UBS Group increased their price objective on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research note on Friday, August 8th. Canaccord Genuity Group decreased their price objective on shares of Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating for the company in a research note on Monday, May 12th. Raymond James Financial increased their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Finally, Royal Bank Of Canada raised their price target on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Nine investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $111.00.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $104.74 on Tuesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The business has a fifty day simple moving average of $98.69 and a two-hundred day simple moving average of $99.58. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The company has a market capitalization of $20.75 billion, a P/E ratio of 25.48, a P/E/G ratio of 2.08 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same period last year, the business posted $2.01 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet’s payout ratio is currently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.